Commonwealth Equity Services LLC raised its holdings in iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report) by 2.1% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,615 shares of the company’s stock after purchasing an additional 283 shares during the period. Commonwealth Equity Services LLC owned 0.63% of iShares U.S. Pharmaceuticals ETF worth $2,386,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds also recently modified their holdings of the company. First Manhattan Co. purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the first quarter valued at approximately $46,000. Blair William & Co. IL purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the first quarter valued at approximately $58,000. Spire Wealth Management lifted its stake in shares of iShares U.S. Pharmaceuticals ETF by 59.5% during the first quarter. Spire Wealth Management now owns 343 shares of the company’s stock valued at $60,000 after buying an additional 128 shares during the period. Ameritas Advisory Services LLC purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the first quarter valued at approximately $68,000. Finally, Koshinski Asset Management Inc. purchased a new position in shares of iShares U.S. Pharmaceuticals ETF during the first quarter valued at approximately $200,000.
iShares U.S. Pharmaceuticals ETF Stock Performance
Shares of IHE opened at $186.67 on Thursday. The company has a market capitalization of $382.66 million, a price-to-earnings ratio of 18.82 and a beta of 0.70. iShares U.S. Pharmaceuticals ETF has a 1 year low of $166.99 and a 1 year high of $191.74. The company’s 50 day simple moving average is $183.55 and its 200 day simple moving average is $179.51.
About iShares U.S. Pharmaceuticals ETF
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Recommended Stories
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- These Quality Dividend Kings Grow their Dividends the Fastest
- What Does Downgrade Mean in Investing?
- 3 Growth Stocks to Buy in September
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 3 Underappreciated Stocks with Nowhere to Go But Up
Want to see what other hedge funds are holding IHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Free Report).
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.